2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

4:30PM-6:00PM: Abstract Number: 997

2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes

4:30PM-6:00PM: Abstract Number: 1045

2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II: Axial Spondyloarthritis – Treatment

4:30PM-6:00PM: Abstract Number: 989

A Randomized Controlled Trial of Rheumatoid Arthritis Risk Disclosure Personalized to Genetics, Autoantibodies, and Lifestyle Among Unaffected First-Degree Relatives: The Personalized Risk Estimator for RA (PRE-RA) Family Study

Epidemiology and Public Health I: Inflammatory Arthritis – Risk and Impact

4:30PM-6:00PM: Abstract Number: 1041

Abatacept in the Treatment of Active Psoriatic Arthritis: 24-Week Results from a Phase III Study

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II: Axial Spondyloarthritis – Treatment

4:30PM-6:00PM: Abstract Number: 1058

Adjustment Profiles Comprising Objective and Subjective Measures in Fibromyalgia Patients

ARHP II: Healthcare Disparities and and Psychosocial Impact on Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1008

Advantageous Effect of an Endogenous Retroviral Envelope Protein in Systemic Lupus Erythematosus with Ex Vivo and In Vivo Anti-Inflammatory Potential

Innate Immunity and Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1046

Anti-TNF Therapy in Axial Spondyloarthritis: Prediction of Therapeutic Responses Using Immunological Signatures

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II: Axial Spondyloarthritis – Treatment

4:30PM-6:00PM: Abstract Number: 1025

Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis

4:30PM-6:00PM: Abstract Number: 990

Autoimmunity to Multiple Antigens Is Expanded in at-Risk Family Members Beyond the Disease Specific Patterns of the SLE or RA Proband

Epidemiology and Public Health I: Inflammatory Arthritis – Risk and Impact

4:30PM-6:00PM: Abstract Number: 1005

Biallelic Hypomorphic Mutations in a Linear Deubiquitinase Define Otulipenia, an Early-Onset Systemic Autoinflammatory Disease

Innate Immunity and Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 998

Brain Responses to Other’s Pain in Fibromyalgia – a Magnetoencephalography (MEG) Study

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes

4:30PM-6:00PM: Abstract Number: 993

Chronic Widespread Pain Associated with Premature Mortality in a UK National Prospective Study

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes

4:30PM-6:00PM: Abstract Number: 1011

Correlations Between B Cell Epitope Specificity and Clinical Features in Patients with Jo-1 Antibodies and the Anti-Synthetase Syndrome

Muscle Biology, Myositis and Myopathies

4:30PM-6:00PM: Abstract Number: 1001

Cytomegalovirus Reactivation in Connective Tissue Disease By Immunosuppressive Therapy Predicts Severe Infection and High Mortality

Infection-related Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1050

Defining Low Disease Activity in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment II: Clinical Trial Design

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].